Send us Feedback

Elan Corporation (ELN)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ELN » Topics » Elans Patented and Commercialized NanoCrystal Technology

This excerpt taken from the ELN 20-F filed Feb 28, 2007.
Elan’s Patented and Commercialized NanoCrystal Technology
 
Elan’s NanoCrystal technology is a drug optimization technology applicable to poorly water-soluble compounds. It is covered by numerous US and international patents and patent applications and is part of a suite of technologies that EDT offers to third-party clients.
 
NanoCrystal technology involves reducing crystalline drug to particles under 400 nanometers. By reducing particle size, the exposed surface area of the drug is increased and is then stabilized to maintain particle size. The drug in nano-form can be incorporated into common dosage forms, including tablets, capsules, inhalation devices, and sterile forms for injection, with the potential for substantial improvements to clinical performance.
 
Products developed and now commercialized in the United States using Elan’s NanoCrystal technology include:
 
  •  Emend® — oral tablet form of aprepitant, a poorly water-soluble compound;
 
  •  Megace® ES — concentrated oral suspension, with reduced dose and improved dissolution and bioavailability;
 
  •  Rapamune® — convenient oral tablet form eliminating reconstitution and refrigerated storage of original compound; and
 
  •  TriCor — new formulation of Abbott’s fenofibrate, which can be taken without regard to food.
 
This excerpt taken from the ELN 20-F filed Mar 30, 2006.
Elan’s Patented and Commercialized NanoCrystal Technology
 
Elan’s NanoCrystal technology is a drug optimization technology applicable to poorly water-soluble compounds. It is covered by more than 130 U.S. and international patents and patent applications and is part of a suite of technologies that EDT offers to third-party clients.
 
Elan’s NanoCrystal technology has offered tangible patient benefits to a number of compounds. For one product, now commercialized the technology improved bioavailability by up to 600 percent; for another launched product, it allowed a four-time reduction in dosage volume; and for others it eliminated the fed-fasting effects providing clear patient benefits to particular therapies.
 
Products developed and now commercialized in the United States using Elan’s patented NanoCrystal technology include:
 
  •  Emend® — oral tablet form of aprepitant, a poorly water-soluble compound;
 
  •  Megace® ES — concentrated oral suspension, with 75 percent reduced dose and improved dissolution and bioavailability;
 
  •  Rapamune® — convenient oral tablet form eliminating reconstitution and refrigerated storage of original compound; and
 
  •  TriCor® — new formulation of Abbott’s fenofibrate, which can be taken without regard to food.
 
We currently have more than 30 products in various stages of development from feasibility through to Phase 3 projects.
 

EXCERPTS ON THIS PAGE:

20-F
Feb 28, 2007
20-F
Mar 30, 2006

RELATED TOPICS for ELN:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki